Join BIOCYTOGEN at CICON 2024
We’re excited to share that we’ll be attending the International Cancer Immunotherapy Conference (CICON) 2024 in Washington, D.C., from September 8th to 11th! As one of the top global events for cancer immunology and immunotherapy, CICON brings together over 1,000 leading experts and innovators from around the world. Don’t miss the opportunity to dive into cutting-edge research and groundbreaking advancements in the field—join us for an inspiring and impactful event!
What is CICON?
The international cancer immunotherapy conference (CICON): translating science into survival, established in 2015, remains the leading platform for groundbreaking research in cancer immunology and immunotherapy. Hosted by the cancer research institute (CRI) and the European network for cancer immunotherapy (ENCI), this conference alternates between the U.S. and Europe. It is led by top experts in the field, drawing over 1,000 specialists in cancer immunology and immunotherapy from around the globe.
Event Overview
Venue: Gaylord National Resort & Convention Center 201 Waterfront Street National Harbor, MD 20745
Dates: September 8th to 11th, 2024
Exhibit Dates and Times:
-
- Sunday, September 8 10 a.m. to 5 p.m
- Monday, September 9 10 a.m. to 5 p.m
- Tuesday, September 10 10 a.m. to 5 p.m
Booth: #1
Event Schedule
CICON24 will focus on the theme of Translating Science into Survival, showcasing prominent plenary sessions by leading experts and selected talks from submitted abstracts. For a detailed view of the daily schedule, including session timings and information on each presentation, please check the program of events.
SUNDAY, SEPTEMBER 8, 2024
-
- 8:00 AM Welcome
- 8:15 AM – 10:05 AM Session 1: Neoadjuvant and Platform Trials
- 10:05 AM – 3:55 PM Session 2:
- Multiomic Data Analysis: Searching for Mechanistic Insights – Beyond just atlas-ing, Part I
- LUNCH AND POSTER SESSION
- Multiomic Data Analysis: Searching for Mechanistic Insights – Beyond just atlas-ing, Part II
- 3:55 PM – 6:25 PM Session 3: Tertiary Lymphoid Aggregates as Regulators of Anti-Cancer Immunity
- 7:00 PM Welcome Reception
MONDAY, SEPTEMBER 9, 2024
-
- 8:00 AM Keynote Address
- 8:40 AM – 10:40 AM Session 4: Cancer Interception – Immune Health and Inflammation as Precursors to Cancer
- 11:10 AM – 1:25 PM Session 5: The Role of Myeloid Cells in the Anti-tumor Response
- 3:00 PM – 4:45 PM Session 6: What’s on the Horizon: New Tools, Technologies, and Approaches in Cancer Immunotherapy, Part I
- 4:45 PM – 5:45 PM Proffered Session: What’s on the Horizon: New Tools, Technologies, and Approaches in Cancer Immunotherapy, Part II
TUESDAY, SEPTEMBER 10, 2024
-
- 8:30 AM William B. Coley Lecture
- 9:10 AM – 12:00 PM Session 7: Metabolic Pathways in the Clinic
- 2:00 PM – 5:15 PM Session 8: Diet and Microbiome
WEDNESDAY, SEPTEMBER 11, 2024
-
- 8:00 AM – 12:00 PM Session 9: Cellular Therapies & Cancer Vaccines: Moving Toward Personalization
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the Cancer Immunotherapy Conference (CICON) in Washington, D.C.!
